4D Molecular Therapeutics, Inc.
FDMT · XNASCIK 1650648fmd_151DQ1H3H48J0G1W1FBE17DBKAManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 28 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Total revenues | 7 | 14 | 18 | 3 | 21 | 0 | 85 |
| Research and development | 39 | 53 | 61 | 80 | 97 | 141 | 196 |
| Total operating expenses | 58 | 70 | 89 | 113 | 134 | 188 | 245 |
| Operating income | (51) | (57) | (71) | (110) | (113) | (188) | (160) |
| Interest and investment income | 2 | 0 | 0 | 3 | 12 | 27 | 19 |
| Other non-operating income (expense) | 1 | (0) | 0 | 3 | 12 | 27 | 19 |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (49) | (57) | (71) | (107) | (101) | (161) | (140) |
| Net income to common shareholders | (49) | (57) | (71) | (107) | (101) | (161) | (140) |